US 12,384,764 B2
Pharmaceutical compounds
Matthew Barrett, Stevenage (GB); George Stuart Cockerill, Stevenage (GB); and James Good, Stevenage (GB)
Assigned to Pfizer Inc., New York, NY (US)
Appl. No. 17/773,136
Filed by Pfizer Inc., New York, NY (US)
PCT Filed Nov. 2, 2020, PCT No. PCT/GB2020/052769
§ 371(c)(1), (2) Date Apr. 29, 2022,
PCT Pub. No. WO2021/084280, PCT Pub. Date May 6, 2021.
Claims priority of application No. 1915932 (GB), filed on Nov. 1, 2019.
Prior Publication US 2022/0380349 A1, Dec. 1, 2022
Int. Cl. C07D 403/12 (2006.01); C07D 403/14 (2006.01)
CPC C07D 403/12 (2013.01) [C07D 403/14 (2013.01)] 16 Claims
 
1. A compound which is a benzodiazepinyl pyrazole of formula (I):

OG Complex Work Unit Chemistry
wherein:
each of R1 and R2 is independently H or halo;
R3 is H, C1-C6 alkyl or —NHR8;
either (i) custom character are all bonds, with custom character and custom character absent; or custom character and custom character are all bonds, with custom character and custom character absent;
R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted;
R5 is H or halo;
R6 is —OR8, —NR8R9 or —R8;
R7 is H or halo;
each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted;
n is 1 or 2; and
one of V, W and X is N or CH and the other two are CH;
or a pharmaceutically acceptable salt thereof.